(NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment in our HARMONi clinical trial, a multi-regional Phase III study sponsored by Summit evaluating ...
The SUMMIT trial enrolled obese patients with heart failure with preserved ejection fraction (HFpEF) – a particularly hard-to-treat form that accounts for around half of all cases of heart ...